WO2006018649A1 - Arene ruthenium (ii) compounds and their use in cancer therapy - Google Patents
Arene ruthenium (ii) compounds and their use in cancer therapy Download PDFInfo
- Publication number
- WO2006018649A1 WO2006018649A1 PCT/GB2005/003242 GB2005003242W WO2006018649A1 WO 2006018649 A1 WO2006018649 A1 WO 2006018649A1 GB 2005003242 W GB2005003242 W GB 2005003242W WO 2006018649 A1 WO2006018649 A1 WO 2006018649A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound according
- alkyl
- carbocyclic
- compound
- ring
- Prior art date
Links
- 0 C*CC*(C)*(C1(C)C(*)=C(*)C(C)=C(C)C(C)=C1)(C=N)*1cc(N)cc(N)c1 Chemical compound C*CC*(C)*(C1(C)C(*)=C(*)C(C)=C(C)C(C)=C1)(C=N)*1cc(N)cc(N)c1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System compounds of the platinum group
- C07F15/0046—Ruthenium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- Ligands A and B may be connected to one another, but they cannot be bound to ligand X.
- C 2-12 alkylene is defined similarly to the definition of the term “alkyl” but includes C 2 to C 12 groups and is a divalent species with radicals separated by two or more (e.g. from two to twelve) carbon atoms linked in a chain.
- the alkylene groups are straight chain groups.
- C 2-12 alkylene groups are optionally substituted in the akylene chain, preferably with one or more phenylene (eg, 1-4- phenylene) and/or -CONR 1a - groups and/or -NR 2a - groups, where R 1a and R 2a independently represent H, Ci -7 alkyl, C 3-20 heterocyclyl or C 5-20 aryl.
- R 1a and R 2a are H or C 1 to C 3 alkyl.
- aryl groups which comprise fused rings include, but are not limited to, groups derived from indane (e.g., 2,3-dihydro-1H- indene) (C 9 ), indene (C 9 ), isoindene (C 9 ), tetraline (1 ,2,3,4-tetrahydronaphthalene (Ci 0 ), acenaphthene (Ci 2 ), fluorene (Ci 3 ), phenalene (Ci 3 ), acephenanthrene (Ci 5 ), and aceanthrene (C 16 ).
- indane e.g., 2,3-dihydro-1H- indene
- indene C 9
- isoindene C 9
- acenaphthene Ci 2
- fluorene Ci 3
- phenalene Ci 3
- monocyclic heteroaryl groups include, but are not limited to, those derived from:
- Ci 4 heteroaryl groups (with 3 fused rings) derived from acridine (N 1 ), xanthene (O-i), thioxanthene (S 1 ), oxanthrene (O 2 ), phenoxathiin (O 1 Si), phenazine (N 2 ), phenoxazine (N 1 O 1 ), phenothiazine (N 1 S 1 ), thianthrene (S 2 ), phenanthridine (N 1 ), phenanthroline (N 2 ), phenazine (N 2 ).
- C 5-2 O aryl groups may optionally be substituted with one or more substituents including, for example, C 1-7 alkyl, C 5-20 aryl, C 3-20 heterocyclyl, cyano, nitro, hydroxyl, ester, halo, thiol, thioether and sulfonate.
- the prefixes e.g., C 3-20 , C 3-7 , C 5-6 , etc.
- the prefixes denote the number of ring atoms, or range of number of ring atoms, whether carbon atoms or heteroatoms.
- the term "Cs- ⁇ heterocyclyl”, as used herein, pertains to a heterocyclyl group having 5 or 6 ring atoms.
- N 1 O 1 tetrahydrooxazole (C 5 ), dihydrooxazole (C 5 ), tetrahydroisoxazole (C 5 ), dihydroisoxazole (C 5 ), morpholine (C 6 ), tetrahydrooxazine (C 6 ), dihydrooxazine (C 6 ), oxazine (C 6 ); N 1 Si: thiazoline (C 5 ), thiazolidine (C 5 ), thiomorpholine (C 6 ); N 2 Oi: oxadiazine (C 6 );
- Halo -F, -Cl, -Br, and -I.
- Amino groups may be primary (-NH 2 ), secondary (-NHR 1 ), or tertiary (-NHR 1 R 2 ), and in cationic form, may be quaternary (- + NR 1 R 2 R 3 ).
- Examples of amino groups include, but are not limited to, -NH 2 , -NHCH 3 , -NHC(CH 3 ) 2 , -N(CHa) 2 , -N(CH 2 CH 3 ) 2 , -NHCH 2 Ph and -NHPh.
- Examples of cyclic amino groups include, but are not limited to, aziridino, azetidino, pyrrolidino, piperidino, piperazino, morpholino, and thiomorpholino.
- Carbocyclic ring refers to a saturated or unsaturated ring, which may be aromatic or non-aromatic, containing from 3 to 8 carbon atoms (preferably 5 to 7 carbon atoms) and includes, for example, cyclopropane, cyclobutane, cyclopentane, cyclohexane and cycloheptane (also see above).
- a reference to a particular compound includes all such isomeric forms, including (wholly or partially) racemic and other mixtures thereof, for example, a mixture enriched in one enantiomer.
- Methods for the preparation (e.g., asymmetric synthesis) and separation (e.g., fractional crystallisation and chromatographic means) of such isomeric forms are either known in the art or are readily obtained by adapting the methods taught herein, or known methods, in a known manner.
- the aldehyde or ketone group is readily regenerated by hydrolysis using a large excess of water in the presence of acid.
- prodrug refers to a compound which, when metabolised (e.g., in vivo), yields the desired active compound.
- the prodrug is inactive, or less active than the active compound, but may provide advantageous handling, administration, or metabolic properties.
- a reference to a particular compound also include prodrugs thereof.
- prodrugs are activated enzymatically to yield the active compound, or a compound which, upon further chemical reaction, yields the active compound (for example, as in ADEPT, GDEPT, LIDEPT, etc.).
- the prodrug may be a sugar derivative or other glycoside conjugate, or may be an amino acid ester derivative.
- the invention provides compounds of formula (I), or solvates or prodrugs thereof ("active compounds”), for use in a method of treatment of the human or animal body.
- a method may comprise administering to such a subject a therapeutically-effective amount of an active compound, preferably in the form of a pharmaceutical composition.
- treatment as used herein in the context of treating a condition, pertains generally to treatment and therapy, whether of a human or an animal (e.g. in veterinary applications), in which some desired therapeutic effect is achieved, for example, the inhibition of the progress of the condition, and includes a reduction in the rate of progress, a halt in the rate of progress, amelioration of the condition, and cure of the condition.
- Treatment as a prophylactic measure i.e. prophylaxis
- prophylaxis is also included.
- terapéuticaally-effective amount refers to that amount of an active compound, or a material, composition or dosage form comprising an active compound, which is effective for producing some desired therapeutic effect, commensurate with a reasonable benefit/risk ratio.
- the active compound or pharmaceutical composition comprising the active compound may be administered to a subject by any convenient route of administration, whether systemically/ peripherally or at the site of desired action, including but not limited to, oral (e.g. by ingestion); topical (including e.g. transdermal, intranasal, ocular, buccal, and sublingual); pulmonary (e.g. by inhalation or insufflation therapy using, e.g. an aerosol, e.g.
- vaginal parenteral, for example, by injection, including subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, and intrasternal; by implant of a depot, for example, subcutaneously or intramuscularly.
- the subject may be a eukaryote, an animal, a vertebrate animal, a mammal, a rodent (e.g. a guinea pig, a hamster, a rat, a mouse), murine (e.g. a mouse), canine (e.g. a dog), feline (e.g. a cat), equine (e.g. a horse), a primate, simian (e.g. a monkey or ape), a monkey (e.g. marmoset, baboon), an ape (e.g. gorilla, chimpanzee, orang-utan, gibbon), or a human.
- a rodent e.g. a guinea pig, a hamster, a rat, a mouse
- murine e.g. a mouse
- canine e.g. a dog
- feline e.g. a cat
- the active compound While it is possible for the active compound to be administered alone, it is preferable to present it as a pharmaceutical composition (e.g. formulation) comprising at least one active compound, as defined above, together with one or more pharmaceutically acceptable carriers, adjuvants, excipients, diluents, fillers, buffers, stabilisers, preservatives, lubricants, or other materials well known to those skilled in the art and optionally other therapeutic or prophylactic agents.
- a pharmaceutical composition e.g. formulation
- the present invention further provides pharmaceutical compositions, as defined above, and methods of making a pharmaceutical composition comprising admixing at least one active compound, as defined above, together with one or more pharmaceutically acceptable carriers, excipients, buffers, adjuvants, stabilisers, or other materials, as described herein.
- pharmaceutically acceptable refers to compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of a subject (e.g. human) without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- a subject e.g. human
- Each carrier, excipient, etc. must also be “acceptable” in the sense of being compatible with the other ingredients of the formulation.
- Suitable carriers, excipients, etc. can be found in standard pharmaceutical texts, for example, Remington's Pharmaceutical Sciences. 18th edition, Mack Publishing Company, Easton, Pa., 1990.
- the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. Such methods include the step of bringing into association the active compound with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active compound with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product.
- Formulations may be in the form of liquids, solutions, suspensions, emulsions, elixirs, syrups, tablets, losenges, granules, powders, capsules, cachets, pills, ampoules, suppositories, pessaries, ointments, gels, pastes, creams, sprays, mists, foams, lotions, oils, boluses, electuaries, or aerosols.
- Formulations suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets, each containing a predetermined amount of the active compound; as a powder or granules; as a solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion; as a bolus; as an electuary; or as a paste.
- a tablet may be made by conventional means, e.g., compression or moulding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared by compressing in a suitable machine the active compound in a free-flowing form such as a powder or granules, optionally mixed with one or more binders (e.g. povidone, gelatin, acacia, sorbitol, tragacanth, hydroxypropylmethyl cellulose); fillers or diluents (e.g. lactose, microcrystalline cellulose, calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc, silica); disintegrants (e.g.
- Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active compound therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach.
- Formulations suitable for topical administration may be formulated as an ointment, cream, suspension, lotion, powder, solution, past, gel, spray, aerosol, or oil.
- a formulation may comprise a patch or a dressing such as a bandage or adhesive plaster impregnated with active compounds and optionally one or more excipients or diluents.
- Formulations suitable for topical administration in the mouth include losenges comprising the active compound in a flavoured basis, usually sucrose and acacia or tragacanth; pastilles comprising the active compound in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active compound in a suitable liquid carrier.
- Formulations suitable for topical administration to the eye also include eye drops wherein the active compound is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active compound.
- Formulations suitable for nasal administration wherein the carrier is a solid, include a coarse powder having a particle size, for example, in the range of about 20 to about 500 microns which is administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
- Suitable formulations wherein the carrier is a liquid for administration as, for example, nasal spray, nasal drops, or by aerosol administration by nebuliser include aqueous or oily solutions of the active compound.
- Formulations suitable for administration by inhalation include those presented as an aerosol spray from a pressurised pack, with the use of a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichoro-tetrafluoroethane, carbon dioxide, or other suitable gases.
- a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichoro-tetrafluoroethane, carbon dioxide, or other suitable gases.
- Formulations suitable for topical administration via the skin include ointments, creams, and emulsions.
- the active compound When formulated in an ointment, the active compound may optionally be employed with either a paraffinic or a water-miscible ointment base.
- the active compounds may be formulated in a cream with an oil-in-water cream base.
- the aqueous phase of the cream base may include, for example, at least about 30% w/w of a polyhydric alcohol, i.e., an alcohol having two or more hydroxy! groups such as propylene glycol, butane-1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol and mixtures thereof.
- the topical formulations may desirably include a compound which enhances absorption or penetration of the active compound through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogues.
- the oily phase may optionally comprise merely an emulsifier (otherwise known as an emulgent), or it may comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil.
- an emulsifier otherwise known as an emulgent
- a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabiliser. It is also preferred to include both an oil and a fat.
- the emulsifier(s) with or without stabiliser(s) make up the so-called emulsifying wax
- the wax together with the oil and/or fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.
- Suitable emulgents and emulsion stabilisers include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate and sodium lauryl sulphate.
- the choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations may be very low.
- the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers.
- Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required.
- mono-isoadipate such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the
- high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.
- Formulations suitable for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.
- Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active compound, such carriers as are known in the art to be appropriate.
- Formulations suitable for parenteral administration include aqueous and non-aqueous isotonic, pyrogen-free, sterile injection solutions which may contain anti-oxidants, buffers, preservatives, stabilisers, bacteriostats, and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non ⁇ aqueous sterile suspensions which may include suspending agents and thickening agents, and liposomes or other microparticulate systems which are designed to target the compound to blood components or one or more organs.
- Suitable isotonic vehicles for use in such formulations include Sodium Chloride Injection, Ringer's Solution, or Lactated Ringer's Injection.
- concentration of the active compound in the solution is from about 1 ng/ml to about 10 ⁇ g/ml, for example from about 10 ng/ml to about 1 ⁇ g/ml.
- the formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets.
- Formulations may be in the form of liposomes or other microparticulate systems which are designed to target the active compound to blood components or one or more organs. Dosage
- appropriate dosages of the active compounds, and compositions comprising the active compounds can vary from patient to patient. Determining the optimal dosage will generally involve the balancing of the level of therapeutic benefit against any risk or deleterious side effects of the treatments of the present invention.
- the selected dosage level will depend on a variety of factors including, but not limited to, the activity of the particular compound, the route of administration, the time of administration, the rate of excretion of the compound, the duration of the treatment, other drugs, compounds, and/or materials used in combination, and the age, sex, weight, condition, general health, and prior medical history of the patient.
- the amount of compound and route of administration will ultimately be at the discretion of the physician, although generally the dosage will be to achieve local concentrations at the site of action which achieve the desired effect without causing substantial harmful or deleterious side-effects.
- Administration in vivo can be effected in one dose, continuously or intermittently (e.g. in divided doses at appropriate intervals) throughout the course of treatment. Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and will vary with the formulation used for therapy, the purpose of the therapy, the target cell being treated, and the subject being treated. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician.
- a suitable dose of the active compound is in the range of about 100 ⁇ g to about 250 mg per kilogram body weight of the subject per day.
- the active compound is a salt, an ester, prodrug, or the like
- the amount administered is calculated on the basis of the parent compound and so the actual weight to be used is increased proportionately.
- cancers which may be treated by the active compounds include, but are not limited to, a carcinoma, for example a carcinoma of the bladder, breast, colon (e.g. colorectal carcinomas such as colon adenocarcinoma and colon adenoma), kidney, epidermal, liver, lung, for example adenocarcinoma, small cell lung cancer and non-small cell lung carcinomas, oesophagus, gall bladder, ovary, pancreas e.g.
- a carcinoma for example a carcinoma of the bladder, breast, colon (e.g. colorectal carcinomas such as colon adenocarcinoma and colon adenoma), kidney, epidermal, liver, lung, for example adenocarcinoma, small cell lung cancer and non-small cell lung carcinomas, oesophagus, gall bladder, ovary, pancreas e.g.
- exocrine pancreatic carcinoma, stomach, cervix, thyroid, prostate, or skin for example squamous cell carcinoma
- a hematopoietic tumour of lymphoid lineage for example leukemia, acute lymphocytic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non- Hodgkin's lymphoma, hairy cell lymphoma, or Burkett's lymphoma
- a hematopoietic tumor of myeloid lineage for example acute and chronic myelogenous leukemias, myelodysplastic syndrome, or promyelocytic leukemia
- thyroid follicular cancer a tumour of mesenchymal origin, for example fibrosarcoma or habdomyosarcoma
- a tumor of the central or peripheral nervous system for example astrocytoma, neuroblastoma, glioma or schwannoma
- Examples of other therapeutic agents that may be administered together (whether concurrently or at different time intervals) with the compounds of the formula (I) include but are not limited to topoisomerase inhibitors, alkylating agents, antimetabolites, DNA binders and microtubule inhibitors (tubulin target agents), such as cisplatin, cyclophosphamide, doxorubicin, irinotecan, fludarabine, 5FU, taxanes, mitomycin C or radiotherapy.
- the two or more treatments may be given in individually varying dose schedules and via different routes.
- the compounds of the formula (I) can be administered simultaneously or sequentially.
- they can be administered at closely spaced intervals (for example over a period of 5-10 minutes) or at longer intervals (for example 1 , 2, 3, 4 or more hours apart, or even longer periods apart where required), the precise dosage regimen being commensurate with the properties of the therapeutic agent(s).
- the compounds of the invention may also be administered in conjunction with non- chemotherapeutic treatments such as radiotherapy, photodynamic therapy, gene therapy; surgery and controlled diets.
- R 1 and R 2 together with the ring to which they are attached form a saturated or unsaturated carbocyclic or heterocyclic group containing up to 3- to 8- membered carbocyclic or heterocyclic rings, wherein each carbocyclic or heterocyclic ring may be fused to one or more other carbocyclic or heterocyclic rings.
- R 3 , R 4 , R 5 and R 6 are H.
- R 1 and R 2 together with the ring to which they are bound in compounds of formula (I) may represent an ortho- or per/ ' -fused carbocyclic or heterocyclic ring system.
- R 1 and R 2 together with the ring to which they are bound may represent a wholly carbocyclic fused ring system such as a ring system containing 2 or 3 fused carbocyclic rings, e.g. optionally substituted, optionally hydrogenated naphthalene or anthracene.
- R 1 and R 2 together with the ring to which they are bound in compounds of formula (I) may represent a fused tricyclic ring such as anthracene or a mono, di, tri, tetra or higher hydrogenated derivative of anthracene.
- R 1 and R 2 together with the ring to which they are bound in formula (I) may represent anthracene, 1 , 4- dihydroanthracene or 1 , 4, 9, 10-tetrahydroanthracene.
- R 1 and R 2 together with the ring to which they are bound in formula (I) may also represent:
- R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are independently selected from H, C 1-7 alkyl, C 5-2O aryl, C 3-20 heterocyclyl, halo, ester, amido, acyl, sulfo, sulfonamido, ether, thioether, azo and amino.
- R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are preferably independently selected from H, C 1-7 alkyl, C 5-20 aryl and ester. Of these H and Ci -7 alkyl (in particular Ci -3 alkyl)are most preferred.
- R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are preferably hydrogen, with the other (if any) groups being selected from Ci -7 alkyl, C 5-20 aryl, C 3-20 heterocyclyl, halo, ester, amido, acyl, sulfo, sulfonamido, ether, thioether, azo and amino, or more preferably Ci -7 alkyl, C 5-20 aryl and ester, and most preferably C 1-7 alkyl (in particular Ci -3 alkyl). If two of R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are not H, then these groups are preferably meta or para to one another, and more preferably para to one another.
- a and B together represent NR N4 R N5 -(CR c1 R C2 ) n -NR N6 R N7 , wherein R C1 and R C2 are independently selected from H and C 1-4 alkyl, R N ⁇ R N5 , R N6 and R N7 are independently selected from H and C 1-4 alkyl, and n is an integer from 1 to 4.
- R 14 and R are both hydrogen.
- n is 2 or 3, more preferably 2.
- R N4 , R N& , R Nb and R N ' are preferably H or methyl and, more preferably, all of R N N 4 4 , r R->N5 R N6 and R N7 are H.
- R N4 is present in A, then p is 0.
- R N4 is absent, then p is I and C takes the place of R N4 .
- R N4 is absent from A, p is I and preferably C is C 4- io alkylene with no substituents (e.g. hexylene).
- n', n", x', x" and y' independently represents an integer from 1 to 12, preferably 1 to 6.
- X is an N-donor ligand
- it is preferably selected from azide, isothiocyanate, and optionally substituted pyridine ligands. Of these, azide and isothiocyanate are preferred.
- the ligand is preferably at least mono-substituted, and may be di-substituted.
- substituents are preferably selected from halo (e.g. chloro, flouro), cyano, and lower alkyl (e.g. methyl). Of these, chloro, cyano and methyl are preferred.
- Preferred substituent patterns include, but are not limited to, 3-, 5-dichloro, 4-cyano and 3-methyl.
- X is an S-donor ligand, it is preferably a thiolate ligand, for example, PhS " .
- the present invention also provides a process for preparing the compounds of the invention which comprises the reaction of a compound of formula [( ⁇ 6 - C 6 (R 1 )(R 2 )(R 3 )(R 4 )(R 5 )(R 6 ))RuABCI]tY q" ], which may be in the form of a monomer or a dimer, with AgNO 3 in a suitable solvent for the reaction, followed by removal of AgCI and reaction with MX, optionally in the presence, or with subsequent addition of, Y q" , in a suitable solvent for the reaction, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X, A, B and Y are as defined above for the compounds of the invention, and M is an appropriate cation, e.g. Na + .
- the filtrate may be purified, for example, by recrystalisation from acetone.
- the following non-limiting examples illustrate the present invention.
- Electrospray lonisation Mass Spectrometry ESI-MS: Positive-ion electrospray ionisation mass spectra were obtained with a Platform Il mass spectrometer (Micromass, Manchester, U.K.). For offline ESI-MS assays, the samples were prepared in 50% CH 3 CN / 50% H 2 O (v/v) and infused directly into the mass spectrometer at 6 ⁇ L min "1 . The ions were produced in an atmospheric pressure ionisation (API) / ESI ion source.
- API atmospheric pressure ionisation
- This complex was prepared by refluxing complex C2 (25.0 mg, 0.0496 mmol) and AgNO 3 (8.4 mg, 0.0494 mmol) in 2.5 mL of a 1 :1 mixture of MeOH and H 2 O for one hour. AgCI was removed by filtration. NaSPh was added (7.9 mg, 0.0595 mmol) and the solution was left overnight. 250 mg of NH 4 PF 6 was added, leading to an orange precipitate. Slow evaporation of the acetone solution of the precipitate led to a crystalline orange product and a yellow powder, both of which, by mass spectrometry, seemed to be the desired compound. Yield: 10.2 mg (36 %). MS: m/z 433.0 for [M - PF 6 J + (CaIc. 433.1 ).
- UV-Vis Ultraviolet and Visible (UV-Vis) Spectroscopy: A Perkin-Elmer Lambda-16 UV-Vis spectrophotometer was used with 1-cm path-length quartz cuvettes (0.5 ml.) and a PTP1 Peltier temperature controller. Spectra were processed using UVWinlab software for Windows' 95.
- A2780 (1 st Method): A2780 cells were plated on day zero, and the complexes to be tested were added on day 3. The complex was removed on day 4 (i.e., 24 h cell exposure), and after growth in fresh medium in the absence of drug, the cells were counted on day 7. The complexes were stored in the dark at 277 K as a precaution against photochemical decomposition. The IC 50 (dose of compound required to cause 50% inhibition of cell growth) values are listed in Table 1.
- A2780 (2 nd method) and A549 Cell line A2780 (human ovarian carcinoma, ECACC 93112519) was maintained in medium comprising RPMI-1640 (Sigma) with 5% Fetal Bovine Serum (Invitrogen), 2mM L-Glutamine (Sigma) and 1% Penicillin / Streptomycin (Invitrogen), in T-75 flasks (Costar).
- Both cell lines were incubated at 37°C, 5% CO 2 , in high humidity.
- A2780 carcinoma cells were seeded (150 ⁇ L) into 96 well plates (Nunc Maxisorp) at 5000 ( ⁇ 10%) cells per well and incubated at 37 0 C, 5% CO 2 in high humidity for 48 hours.
- A549 carcinoma cells were seeded (150 ⁇ l_) into 96 well plates (Nunc Maxisorp) at 2000 (+ 10%) cells per well and incubated at 37 0 C, 5% CO 2 in high humidity for 24 hours.
- the compounds to be tested were solubilised by sonication in DMSO (Fisher Scientific) to provide 2OmM solutions.
- Compounds were serially diluted with DMSO before diluting in cell culture medium to give concentrations four-fold greater than the final concentrations required in the assay.
- the dilutions of compound in culture medium were added to the cell plates (50 ⁇ l_) in triplicates to achieve final concentrations of 100 ⁇ M, 50 ⁇ M, 10 ⁇ M, 5 ⁇ M, 1 ⁇ M and 0.1 ⁇ M.
- the final DMSO concentration in each well was 0.5% (v/v).
- the plates were incubated for 24 hours at 37°C, 5% CO 2 , in high humidity.
- the cells were washed (200 ⁇ L) twice with sterile phosphate buffered Saline (Sigma) and the cell culture medium replenished (200 ⁇ l_). Plates were incubated at 37°C, 5% CO 2 , in high humidity for 96 hours. After the incubation surviving cells were fixed by the addition of 50%(w/v) Trichloroacetic acid (50 ⁇ L) and incubated at 4°C for 1 hour. Plates were washed three times with excess tap water and air-dried.
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002578280A CA2578280A1 (en) | 2004-08-20 | 2005-08-19 | Arene ruthenium (ii) compounds and their use in cancer therapy |
MX2007002099A MX2007002099A (en) | 2004-08-20 | 2005-08-19 | Arene ruthenium (ii) compounds and their use in cancer therapy. |
US11/660,627 US20080096846A1 (en) | 2004-08-20 | 2005-08-19 | Arene Ruthenium (ll) Compounds And Their Use In Cancer Therapy |
BRPI0514430-2A BRPI0514430A (en) | 2004-08-20 | 2005-08-19 | ruthenium compound (ii) or a solvate or prodrug thereof, composition, use of a compound, and method of treating an individual suffering from cancer |
AU2005273726A AU2005273726A1 (en) | 2004-08-20 | 2005-08-19 | Arene ruthenium (II) compounds and their use in cancer therapy |
JP2007526570A JP2008510693A (en) | 2004-08-20 | 2005-08-19 | Arene ruthenium (II) compounds and their use in the treatment of cancer |
EP05771813A EP1786412A1 (en) | 2004-08-20 | 2005-08-19 | Arene ruthenium (ii) compounds and their use in cancer therapy |
NO20071481A NO20071481L (en) | 2004-08-20 | 2007-03-20 | Aren-ruthenium (II) compounds and their use in cancer therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0418643.3A GB0418643D0 (en) | 2004-08-20 | 2004-08-20 | Ruthenium (II) compounds |
GB0418643.3 | 2004-08-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006018649A1 true WO2006018649A1 (en) | 2006-02-23 |
Family
ID=33042406
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2005/003242 WO2006018649A1 (en) | 2004-08-20 | 2005-08-19 | Arene ruthenium (ii) compounds and their use in cancer therapy |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1786412A1 (en) |
JP (1) | JP2008510693A (en) |
KR (1) | KR20070060091A (en) |
CN (1) | CN101043885A (en) |
AU (1) | AU2005273726A1 (en) |
BR (1) | BRPI0514430A (en) |
CA (1) | CA2578280A1 (en) |
GB (1) | GB0418643D0 (en) |
MX (1) | MX2007002099A (en) |
NO (1) | NO20071481L (en) |
WO (1) | WO2006018649A1 (en) |
ZA (1) | ZA200702093B (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007128158A1 (en) | 2006-05-09 | 2007-11-15 | Ecole Polytechnique Federale De Lausanne (Epfl) | Transition metal complexes for inhibiting resistance in the treatment of cancer and metastasis |
WO2007118774A3 (en) * | 2006-04-13 | 2008-03-20 | Wacker Chemie Ag | Novel ru complexes, production and use thereof |
WO2008155531A1 (en) * | 2007-06-19 | 2008-12-24 | Oxford Biosensors Ltd | Redox mediators |
EP2067771A1 (en) | 2007-12-03 | 2009-06-10 | EPFL Ecole Polytechnique Fédérale de Lausanne | Derivatives of Dihydroxypyrrolidine as Anti-Cancer Compounds |
EP2409697A1 (en) | 2010-07-20 | 2012-01-25 | Université de Neuchâtel | Medicaments Based on Dinuclear Ruthenium, Osmium and Iron Complexes Comprising Triply Bridging Thiolato, Selenolato, Alkoxo and/or Amido Ligands |
WO2013038395A1 (en) | 2011-09-16 | 2013-03-21 | Universidade De Lisboa | Transition metal complexes for pharmaceutical applications |
WO2013136296A2 (en) | 2012-03-14 | 2013-09-19 | Universidade De Lisboa | Water-soluble organometallic ruthenium and iron compunds presenting heteroaromatic ligands |
US9751081B2 (en) | 2014-12-01 | 2017-09-05 | Clemson University | Self-regenerating antioxidant catalysts and methods of using the same |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2976347B1 (en) | 2013-03-15 | 2022-01-19 | McFarland, Sherri Ann | Metal-based coordination complexes as photodynamic compounds and their use |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001030790A1 (en) * | 1999-10-27 | 2001-05-03 | The University Court, The University Of Edinburgh | Half-sandwich ruthenium (ii) compounds comprising nitrogen containing ligands for treatment of cancer |
WO2002002572A1 (en) * | 2000-06-30 | 2002-01-10 | The University Court, The University Of Edinburgh | Ruthenium (ii) compounds for use in the therapy of cancer |
WO2004005304A1 (en) * | 2002-07-05 | 2004-01-15 | The University Court, The University Of Edinburgh | Ruthenium anticancer complexes |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19736152A1 (en) * | 1997-08-14 | 1999-02-18 | Martin Wehlan | New azido-aziridine complex compounds |
-
2004
- 2004-08-20 GB GBGB0418643.3A patent/GB0418643D0/en not_active Ceased
-
2005
- 2005-08-19 AU AU2005273726A patent/AU2005273726A1/en not_active Abandoned
- 2005-08-19 EP EP05771813A patent/EP1786412A1/en not_active Withdrawn
- 2005-08-19 KR KR1020077006364A patent/KR20070060091A/en not_active Application Discontinuation
- 2005-08-19 WO PCT/GB2005/003242 patent/WO2006018649A1/en active Application Filing
- 2005-08-19 JP JP2007526570A patent/JP2008510693A/en active Pending
- 2005-08-19 CN CNA2005800355417A patent/CN101043885A/en active Pending
- 2005-08-19 MX MX2007002099A patent/MX2007002099A/en not_active Application Discontinuation
- 2005-08-19 CA CA002578280A patent/CA2578280A1/en not_active Abandoned
- 2005-08-19 BR BRPI0514430-2A patent/BRPI0514430A/en not_active IP Right Cessation
-
2007
- 2007-03-12 ZA ZA200702093A patent/ZA200702093B/en unknown
- 2007-03-20 NO NO20071481A patent/NO20071481L/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001030790A1 (en) * | 1999-10-27 | 2001-05-03 | The University Court, The University Of Edinburgh | Half-sandwich ruthenium (ii) compounds comprising nitrogen containing ligands for treatment of cancer |
WO2002002572A1 (en) * | 2000-06-30 | 2002-01-10 | The University Court, The University Of Edinburgh | Ruthenium (ii) compounds for use in the therapy of cancer |
WO2004005304A1 (en) * | 2002-07-05 | 2004-01-15 | The University Court, The University Of Edinburgh | Ruthenium anticancer complexes |
Non-Patent Citations (8)
Title |
---|
CHEN H ET AL: "Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 124, no. 12, 27 March 2002 (2002-03-27), pages 3064 - 3082, XP002259900, ISSN: 0002-7863 * |
CHEN HAIMEI ET AL: "Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms.", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 125, no. 1, 8 January 2003 (2003-01-08), pages 173 - 186, XP002359478, ISSN: 0002-7863 * |
CHEN HAIMEI ET AL: "Induced-fit recognition of DNA by organometallic complexes with dynamic stereogenic centers.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 100, no. 25, 9 December 2003 (2003-12-09), pages 14623 - 14628, XP002359477, ISSN: 0027-8424 * |
FERNANDEZ RAFAEL ET AL: "Use of chelating ligands to tune the reactive site of half-sandwich ruthenium(II)-arene anticancer complexes", CHEMISTRY - A EUROPEAN JOURNAL, vol. 10, no. 20, 11 October 2004 (2004-10-11), pages 5173 - 5179, XP002359476, ISSN: 0947-6539 * |
HAYASHIDA, TAIZO ET AL: "Isolable yet highly reactive cationic organoruthenium(II) amidinates, [Ru(.eta.6-C6R6)(.eta.-amidinate)]+X-, showing signs of coordinative unsaturation: isoelectronic complexes of Ru(.eta.5-C5Me5)(.eta.-amidinate)", CHEMISTRY LETTERS, no. 10, 2001, pages 954 - 955, XP002359480, ISSN: 0366-7022 * |
MORRIS ET AL: "Inhibition of Cancer Cell Growth by Ruthenium(II) Arene Complexes", JOURNAL OF MEDICINAL CHEMISTRY, vol. 44, no. 1, 25 October 2001 (2001-10-25), pages 3616 - 3621, XP002293723, ISSN: 0022-2623 * |
SOLORZANO, CARMEN ET AL: "Preparation of arene ruthenium(II) complexes with activated ligands for protein labeling", INORGANICA CHIMICA ACTA, vol. 97, no. 2, 1985, pages 135 - 141, XP000980284, ISSN: 0020-1693 * |
WANG FUYI ET AL: "Reactions of a ruthenium(II) arene antitumor complex with cysteine and methionine.", INORGANIC CHEMISTRY, vol. 41, no. 17, 26 August 2002 (2002-08-26), pages 4509 - 4523, XP002359479, ISSN: 0020-1669 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007118774A3 (en) * | 2006-04-13 | 2008-03-20 | Wacker Chemie Ag | Novel ru complexes, production and use thereof |
US8124711B2 (en) | 2006-04-13 | 2012-02-28 | Wacker Chemie Ag | Ru complexes, production and use thereof |
US9018199B2 (en) | 2006-05-09 | 2015-04-28 | Ecole Polytechnique Federale De Lausanne (Epfl) | Transition metal complexes for inhibiting resistance in the treatment of cancer and metastasis |
WO2007128158A1 (en) | 2006-05-09 | 2007-11-15 | Ecole Polytechnique Federale De Lausanne (Epfl) | Transition metal complexes for inhibiting resistance in the treatment of cancer and metastasis |
US8618293B2 (en) | 2007-06-19 | 2013-12-31 | Roche Diagnostics Operations, Inc. | Redox mediators |
WO2008155531A1 (en) * | 2007-06-19 | 2008-12-24 | Oxford Biosensors Ltd | Redox mediators |
JP2010531976A (en) * | 2007-06-19 | 2010-09-30 | オックスフォード バイオセンサーズ リミテッド | Redox mediator |
EP2067771A1 (en) | 2007-12-03 | 2009-06-10 | EPFL Ecole Polytechnique Fédérale de Lausanne | Derivatives of Dihydroxypyrrolidine as Anti-Cancer Compounds |
WO2012010616A1 (en) | 2010-07-20 | 2012-01-26 | Université De Neuchâtel | Medicaments based on dinuclear arene ruthenium complexes comprising bridging thiolato, selenolato or alkoxo ligands |
EP2409697A1 (en) | 2010-07-20 | 2012-01-25 | Université de Neuchâtel | Medicaments Based on Dinuclear Ruthenium, Osmium and Iron Complexes Comprising Triply Bridging Thiolato, Selenolato, Alkoxo and/or Amido Ligands |
WO2013038395A1 (en) | 2011-09-16 | 2013-03-21 | Universidade De Lisboa | Transition metal complexes for pharmaceutical applications |
WO2013136296A2 (en) | 2012-03-14 | 2013-09-19 | Universidade De Lisboa | Water-soluble organometallic ruthenium and iron compunds presenting heteroaromatic ligands |
US9751081B2 (en) | 2014-12-01 | 2017-09-05 | Clemson University | Self-regenerating antioxidant catalysts and methods of using the same |
Also Published As
Publication number | Publication date |
---|---|
KR20070060091A (en) | 2007-06-12 |
CA2578280A1 (en) | 2006-02-23 |
GB0418643D0 (en) | 2004-09-22 |
EP1786412A1 (en) | 2007-05-23 |
BRPI0514430A (en) | 2008-05-06 |
AU2005273726A1 (en) | 2006-02-23 |
MX2007002099A (en) | 2007-04-24 |
ZA200702093B (en) | 2008-08-27 |
NO20071481L (en) | 2007-05-16 |
JP2008510693A (en) | 2008-04-10 |
CN101043885A (en) | 2007-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006018649A1 (en) | Arene ruthenium (ii) compounds and their use in cancer therapy | |
Bierbach et al. | Modification of platinum (II) antitumor complexes with sulfur ligands. 1. Synthesis, structure, and spectroscopic properties of cationic complexes of the types [PtCl (diamine)(L)] NO3 and [{PtCl (diamine)} 2 (LL)](NO3) 2 (L= monofunctional thiourea derivative; LL= bifunctional thiourea derivative) | |
EP2146977B1 (en) | Synthesis of cyclic carbonates in the presence of dimeric aluminium (salen) catalysts | |
EP1991556A1 (en) | Ruthenium (ii) compounds | |
Garrison et al. | Synthesis and crystallographic characterization of multi-donor N-heterocyclic carbene chelating ligands and their silver complexes: Potential use in pharmaceuticals | |
EP2408784B1 (en) | Aluminum complexes and their use in the synthesis of cyclic carbonates | |
US20090186864A1 (en) | Ruthenium (ii) compounds | |
US20080096846A1 (en) | Arene Ruthenium (ll) Compounds And Their Use In Cancer Therapy | |
Khalid et al. | Structure and surface analyses of a newly synthesized acyl thiourea derivative along with its in silico and in vitro investigations for RNR, DNA binding, urease inhibition and radical scavenging activities | |
EP1958951A1 (en) | Phosphine transition metal complex, method for producing same and antitumor agent containing same | |
Pörschke | Coupling of Two Ethyne Molecules at a Nickel Center to Form a Nickelacyclopentadiene Complex | |
US9598448B2 (en) | Osmium (II) arene imino anti-cancer complexes | |
WO2004101506A1 (en) | Glyoxalase inhibitors | |
WO2010024783A1 (en) | Biarylrhodanine and pyridylrhodanine compounds and their use | |
JPH06510520A (en) | Novel platinum (II) complex compound and method for producing the same | |
Korostylev et al. | New palladium (II) complexes of (N, N-dimethylamino) alkoxy-1, 3, 2-oxazaphospholidine ligands | |
Erker et al. | Structures and dynamic features of dinuclear tartratozirconocene complexes | |
Romańczyk et al. | Redox activity of bimetallic complexes based on tris (3, 5-dimethylpyrazolyl) borato molybdenum (II) and tungsten (II) nitrosyls. Complexes derived from ethane-1, 2-diol and the crystal structure of anti-[Mo (NO){HB (3, 5-Me2C3HN2) 3}(OCH2CH2O)] 2· 4CHCl3 | |
Lim et al. | Palladium (II) and platinum (II) complexes containing dimesyloxy-substituted chiral diamines | |
Crawford et al. | Metalation reactions: VI. Metalation of substituted ferrocenes with methylpentacarbonyl-manganese and-rhenium; formation of homoannular metalated ferrocenes and of the novel ferrocenylmethyl (methyl) aminomethylenetetracarbonylmanganese | |
JPS62234020A (en) | Antitumor agent | |
JPH0469393A (en) | New platinum complex and tumor treating agent comprising the same complex as active ingredient | |
JPS62158211A (en) | Antitumor agent | |
JPH0144195B2 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2578280 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 553161 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005273726 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007526570 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/002099 Country of ref document: MX Ref document number: 11660627 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1459/DELNP/2007 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2005273726 Country of ref document: AU Date of ref document: 20050819 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005273726 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005771813 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077006364 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580035541.7 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005771813 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11660627 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0514430 Country of ref document: BR |